Mayur S. Ramesh, MD, Henry Ford Hospital System, Detroit, MI; Bharat Misra, MD, Borland-Groover Clinic, Jacksonville, FL; Arnab Ray, MD, Robert Smith, MD, Ochsner Clinic, New Orleans, LA; Mary Kay Sobcinski, RN, MHA, Rebiotix Inc, Roseville, MN
Download this poster (697 KB)
Download the abstract (342 KB)
American College of Gastroenterology
October 17-20, 2014, Philadelphia, PA
The purpose of the PUNCH CD study was to assess the safety of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection. RBX2660 is a biologic drug consisting of a suspension of live human-derived intestinal microbes. A secondary objective of the study was Clostridium difficile infection resolution at 8 weeks.